Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 34

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 34
---
 strain of COVID-19, also known as coronavirus,
was reported in Wuhan, China. Initially the outbreak was largely concentrated in China, but it rapidly spread to countries across the
globe, including in Israel and the United States. Many countries around the world, including in Israel and the United States, implemented
significant governmental measures to control the spread of the virus, including temporary closure of businesses, severe restrictions
on travel and the movement of people, and other material limitations on the conduct of business.

If
there is a resurgence of COVID-19 its spread may materially affect us economically. While the potential economic
impact brought by, and the duration of, any future resurgence of the COVID-19 pandemic may be difficult to assess or predict, it has
already caused, and could result in further, significant disruption of global financial markets, reducing our ability to access capital,
which could in the future negatively affect our liquidity and financial position. In addition, the trading prices for other companies
have been highly volatile as a result of the COVID-19 pandemic. As a result, we may face difficulties raising capital through sales of
our Ordinary Shares or other securities and such sales may be on unfavorable terms. To the extent that future waves of COVID-19 disrupt
normal business operations, we may face operational challenges with our services, and we likely will have to adopt remote working and
workplace protocols for employees in accordance with government requirements and other measures to minimize such impact.

The
extent to which COVID-19 impacts our operations will depend on future developments, which are highly uncertain and cannot be predicted
with confidence, including the duration and severity of the outbreak, and the actions that may be required to contain COVID-19 or treat
its impact. In particular, the extent to which any resurgence of the COVID-19 pandemic may impact our business and financial performance
will depend on future developments, which are highly uncertain and cannot be predicted with confidence.

<div align='center'>26</div>

Risks Related to Our Reliance on Third Parties

We will rely on third parties to conduct certain elements of our preclinical studies and clinical trials and perform other tasks for us. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates.

We rely upon third-party
vendors, including CROs, to monitor and manage data for our ongoing preclinical studies and clinical trials. If our CROs do not